Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
MeVis Medical Solutions AG's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was -478.89%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for MeVis Medical Solutions AG's 3-Year ROIIC % or its related term are showing as below:
FRA:M3V's 3-Year ROIIC % is ranked worse than 97.41% of 617
companies
in the Healthcare Providers & Services industry
Industry Median: 3.46
vs FRA:M3V: -478.89
MeVis Medical Solutions AG (FRA:M3V) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
MeVis Medical Solutions AG 3-Year ROIIC % Related Terms
MeVis Medical Solutions AG 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M3V vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, MeVis Medical Solutions AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2.261201 (Sep. 2025) - 6.39883 (Sep. 2022) )
/
( 19.081 (Sep. 2025) - 18.217 (Sep. 2022) )
=
-4.137629
/
0.864
=
-478.89%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
MeVis Medical Solutions AG (FRA:M3V) has a 3-Year ROIIC % of -478.89 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MeVis Medical Solutions AG and its competitors. According to the industry distribution chart, MeVis Medical Solutions AG ranks #601 out of 617 companies in the Healthcare Providers & Services industry, placing it in the top 97.4%.
Is MeVis Medical Solutions AG's 3-Year ROIIC % too high?
MeVis Medical Solutions AG's current 3-Year ROIIC % is -478.89. Based on the distribution chart, MeVis Medical Solutions AG ranks #601 out of 617 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MeVis Medical Solutions AG ranks #601 out of 617 companies for 3-Year ROIIC %. This places MeVis Medical Solutions AG in the lower half of its industry. The industry median 3-Year ROIIC % is 3.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.46, based on 617 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MeVis Medical Solutions AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeVis Medical Solutions AG's current 3-Year ROIIC % is -478.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current 3-Year ROIIC % of -478.89. The stock's GF Value™ is €22.72, compared to a current price of €24.00 — trading 5.6% above its estimated fair value. The current 3-Year ROIIC % is -478.89. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current 3-Year ROIIC % is -478.89 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €24.00 is trading 5.6% above its estimated GF Value™ of €22.72.
Key valuation signals for FRA:M3V:
3-Year ROIIC %: -478.89
GF Value™: €22.72 vs. price of €24.00 (5.6% above fair value)
No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score
Get the complete analysis for FRA:M3V
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M3V has been successfully added to your 
